Vol. 2 No. 3 (2022)
Reimbursement Recommendations

Estradiol and Progesterone Capsule (Bijuva)

Published March 1, 2022

Key Messages

  • CADTH recommends that Bijuva be reimbursed by public drug plans for the treatment of patients with moderate-to-severe vasomotor symptoms (VMS) associated with menopause if certain conditions are met.
  • Bijuva should only be covered to treat patients who have moderate-to-severe VMS associated with menopause and have an intact uterus.
  • Bijuva should be reimbursed in a similar way to Bijuva’s individual components and all other forms of oral hormone replacement therapy (HRT) and should only be reimbursed if the cost of Bijuva provides savings for the drug plans relative to the cost of treatment with estradiol and progesterone as individual components.